相关实验视频

Updated: May 20, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

通过Piperlongumine针对EGFR-Mcl-1轴作为非小细胞肺癌治疗的新策略

Wen Liu¹, Zhibin Jiang², Ruirui Wang¹

¹Department of Radiology, The Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, P. R. China.

The American journal of Chinese medicine

|March 27, 2025

概括

皮珀龙胺有效抑制非小细胞肺癌 (NSCLC) 细胞,并通过诱导亡来克服奥西默提尼布的耐药性. 这种化合物显示出治疗EGFR突变NSCLC的前景,即使在耐药病例中也是如此.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 提出了重要的治疗耐药性挑战.
针对表皮生长因子受体 (EGFR) 的向疗法,如奥西默提尼布,至关重要,但面临抵抗.
需要新的治疗策略来克服NSCLC治疗中的耐药性.

研究的目的:

调查Piperlongumine作为一种潜在的治疗剂,以克服NSCLC中的Osimertinib耐药性.
阐明皮珀龙胺在NSCLC细胞中发挥抗癌作用的分子机制.
在临床前NSCLC模型中评估Piperlongumine的疗效.

主要方法:

在体外激酶试验中评估Piperlongumine对EGFR活性的影响.
亡测定和西方抹杀来分析信号通路和蛋白质表达.
NSCLC异种移植模型 (对osimertinib敏感和耐药) 以评估体内疗效.

主要成果:

皮珀龙胺在野生类型和耐药突变物中抑制了EGFR激酶活性.
皮珀龙胺通过Akt-GSK3β通路降低Mcl-1的调节诱导了内在亡.
皮珀龙胺通过增强与β-TRCP的相互作用促进了Mcl-1降解.
皮珀龙明在敏感和耐性NSCLC异种移植中显著抑制了瘤生长.

结论:

皮珀龙胺显示出强大的抗癌活性,对抗NSCLC,包括对奥西默提尼布耐药的形式.
皮珀龙胺通过诱导Mcl-1降解和亡来克服EGFR向治疗的耐药性.
Piperlongumine 在NSCLC治疗中具有显著的临床应用潜力,特别是在耐药病例中.

关键词:

在Mcl-1中.非小细胞肺癌非小细胞肺癌奥西默蒂尼布 (Osimertinib) 是一种药物.Piperlongumine 是一种长时间的.在Ubiquitination中使用.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...